ADAM9 Inhibition Increases Membrane Activity of ADAM10 and Controls α-Secretase Processing of Amyloid Precursor Protein

ADAMs and ADAMTSs in cancer

(2016) S.L. Turner et al.   BRITISH JOURNAL OF BIOMEDICAL SCIENCE

Regulated intramembrane proteolysis - lessons from amyloid precursor protein processing

(2011) Stefan F. Lichtenthaler et al.   JOURNAL OF NEUROCHEMISTRY

Cross-domain inhibition of TACE ectodomain

(2011) C. J. Tape et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Metalloprotease-Disintegrin ADAM8 Is Essential for the Development of Experimental Asthma

(2010) Silvia Naus et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2)

(2010) Marie Kveiborg et al.   BIOCHEMICAL JOURNAL

Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9

(2010) Marcia L. Moss et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons

(2010) Peer-Hendrik Kuhn et al.   EMBO JOURNAL

The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: Novel drug targets with therapeutic potential?

(2010) Paul Saftig et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities

(2010) Miles A. Miller et al.   Integrative Biology

Tumor Necrosis Factor-  (TNF- ) Regulates Shedding of TNF-  Receptor 1 by the Metalloprotease-Disintegrin ADAM8: Evidence for a Protease-Regulated Feedback Loop in Neuroprotection

(2010) J. W. Bartsch et al.   JOURNAL OF NEUROSCIENCE

A Mutated Soluble Neuropilin-2 B Domain Antagonizes Vascular Endothelial Growth Factor Bioactivity and Inhibits Tumor Progression

(2010) E. Geretti et al.   MOLECULAR CANCER RESEARCH

ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties

(2010) April A. N. Rose et al.   PLoS One

Neuropilin-2 acts as a modulator of Sema3A-dependent glioma cell migration

(2010) Cécile Nasarre et al.   Cell Adhesion & Migration

Soluble neuropilin-2, a nerve repellent receptor, is increased in rheumatoid arthritis synovium and aggravates sympathetic fiber repulsion and arthritis

(2009) Alexander Fassold et al.   ARTHRITIS AND RHEUMATISM

Mac-1 (CD11b/CD18) Links Inflammation and Thrombosis After Glomerular Injury

(2009) Junichi Hirahashi et al.   CIRCULATION

ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies

(2009) Garrit Koller et al.   CURRENT PHARMACEUTICAL DESIGN

ADAM10 as a Therapeutic Target for Cancer and Inflammation

(2009) Howard Crawford et al.   CURRENT PHARMACEUTICAL DESIGN

ADAM17 as a Therapeutic Target in Multiple Diseases

(2009) Joaquin Arribas et al.   CURRENT PHARMACEUTICAL DESIGN

Role of ADAMs in the Ectodomain Shedding and Conformational Conversion of the Prion Protein

(2009) David R. Taylor et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ADAM10, the Rate-limiting Protease of Regulated Intramembrane Proteolysis of Notch and Other Proteins, Is Processed by ADAMS-9, ADAMS-15, and the γ-Secretase

(2009) Thomas Tousseyn et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Complement Receptor 3 Promotes Severe Ross River Virus-Induced Disease

(2008) T. E. Morrison et al.   JOURNAL OF VIROLOGY

The ADAM metalloproteinases

(2008) D EDWARDS et al.   MOLECULAR ASPECTS OF MEDICINE

Presenilin: RIP and beyond

(2008) Matthew R. Hass et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

(2008) Marcia L Moss et al.   Nature clinical practice. Rheumatology